Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Squamous Cell Carcinoma of Head and Neck 30Oropharyngeal Neoplasms 21Nasopharyngeal Carcinoma 16Head and Neck Neoplasms 13Prostatic Neoplasms 12Laryngeal Neoplasms 9Carcinoma, Non-Small-Cell Lung 9Carcinoma, Squamous Cell 8Carcinoma 8Breast Neoplasms 8Rectal Neoplasms 7Mouth Neoplasms 7Hypopharyngeal Neoplasms 7Glioma 6Glioblastoma 6Uterine Cervical Neoplasms 5Papillomavirus Infections 5Esophageal Neoplasms 5Urinary Bladder Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Nasopharyngeal Neoplasms 4Astrocytoma 4Mesothelioma, Malignant 3Lymphatic Metastasis 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Endometrial Neoplasms 3Brain Neoplasms 3Tumor Virus Infections 2Tongue Neoplasms 2

Interventions

pembrolizumab 1fludarabine 1Radiotherapy, Intensity-Modulated 1Losartan 1LY3300054 1Gemcitabine 1Cyclophosphamide 1Cisplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Camurati-Engelmann Syndrome × Radiotherapy, Intensity-Modulated × 1 year × Clear all
NCT02937272 2026-04-03

A Study of LY3200882 in Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
223 enrolled

Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡